University of Sydney
2022 - Research.com Rising Star of Science Award
Internal medicine, Melanoma, Ipilimumab, Oncology and Pembrolizumab are his primary areas of study. His biological study spans a wide range of topics, including Surgery and Immunology. His Melanoma research integrates issues from Cancer and Immunotherapy.
His study in Cancer is interdisciplinary in nature, drawing from both Biopsy and Pathology. His studies in Ipilimumab integrate themes in fields like Discontinuation and Response Evaluation Criteria in Solid Tumors. He interconnects Biomarker, V600E and Hazard ratio in the investigation of issues within Oncology.
The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Ipilimumab and Immunotherapy. The Melanoma study combines topics in areas such as Cancer, Targeted therapy and Immunology. Many of his studies on Internal medicine apply to Gastroenterology as well.
His studies deal with areas such as Adjuvant therapy, Metastatic melanoma, Surgery and Cohort as well as Oncology. His Ipilimumab research is multidisciplinary, incorporating perspectives in Advanced melanoma, Adjuvant, Clinical endpoint, Toxicity and Combination therapy. His Adverse effect research is multidisciplinary, incorporating elements of Immunosuppression and Discontinuation.
Alexander M. Menzies mainly focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Nivolumab. He usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Adverse effect and Immunosuppression. His Melanoma research includes themes of Immune checkpoint, Targeted therapy, Interquartile range and Confidence interval.
His research in Oncology focuses on subjects like Metastatic melanoma, which are connected to PALB2, Mutation, Partial response and Somatic cell. The various areas that he examines in his Ipilimumab study include Pembrolizumab, Metastasis and Systemic therapy. The study incorporates disciplines such as Neoadjuvant therapy and Clinical trial in addition to Nivolumab.
His main research concerns Internal medicine, Melanoma, Ipilimumab, Nivolumab and Oncology. Retrospective cohort study and Cohort study are among the areas of Internal medicine where the researcher is concentrating his efforts. His work is dedicated to discovering how Retrospective cohort study, Cause of death are connected with Cancer and other disciplines.
He interconnects Positron emission tomography and Histopathology in the investigation of issues within Melanoma. His work deals with themes such as Pembrolizumab and Systemic therapy, which intersect with Ipilimumab. His Nivolumab study which covers Targeted therapy that intersects with Clinical trial, Surrogate endpoint and Neoadjuvant therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Daniel Y. Wang;Joe Elie Salem;Joe Elie Salem;Justine V. Cohen;Sunandana Chandra.
JAMA Oncology (2018)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long;Alexander M. Menzies;Adnan M. Nagrial;Lauren E. Haydu.
Journal of Clinical Oncology (2011)
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz.
Journal of Clinical Oncology (2017)
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Georgina V Long;Victoria Atkinson;Serigne Lo;Shahneen Sandhu.
Lancet Oncology (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson.
Annals of Oncology (2017)
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino.
JAMA Oncology (2016)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak.
Lancet Oncology (2018)
BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact.
Helen Rizos;Alexander M. Menzies;Gulietta M. Pupo;Matteo S. Carlino.
Clinical Cancer Research (2014)
Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
Alexander M. Menzies;Lauren E. Haydu;Lydia Visintin;Lydia Visintin;Lydia Visintin;Matteo S. Carlino;Matteo S. Carlino.
Clinical Cancer Research (2012)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Jason Madore;Ricardo E. Vilain;Ricardo E. Vilain;Alexander M. Menzies;Hojabr Kakavand.
Pigment Cell & Melanoma Research (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: